Newbury Pharmaceuticals is strengthening its portfolio with Levodopa/Benserazide
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2023-09-22 10:00:00
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Levodopa/Benserazide tablets.
“This combination of medicines is used to treat Parkinson’s disease. People with Parkinson’s disease do not have enough dopamine in certain parts of their brains. This can result in slow movements, stiff muscles and tremor. With the addition of Levodopa/Benserazide we have also secured a new partnership which can be used to source additional new products” says Mr Lars Minor CEO, Newbury Pharmaceuticals.
Regulatory filling will take place in the near future, and we aim to launch this medicine in Sweden where the total annual value of the market is estimated to be 4 MEUR according to DLMI Nordic Pharma Insights.
Newbury currently has over thirty (30) products in its portfolio and the first launches took place in 2022 with additional launches planned in a steady stream over the coming years.